P163 Efficacy of deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor, in musculoskeletal manifestations of systemic lupus erythematosus: a subanalysis of the phase 2 PAISLEY study
Marilyn C. Pike(Bethesda Hospital), Joan T. Merrill(Oklahoma Medical Research Foundation), Thomas Wegman(Bristol-Myers Squibb (United States)), Coburn Hobar(Bristol-Myers Squibb (United States)), Richard Furie(Hofstra University), Thomas Dörner(German Rheumatism Research Centre), R. Koti(Syneos Health (United States)), Subhashis Banerjee(Bristol-Myers Squibb (United States)), Amit Saxena(Shree Guru Gobind Singh Tricentenary University), Samantha Pomponi(Bristol-Myers Squibb (United States)), Peter Nash(Griffith University)
Cited by 0
Related Papers
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
|Annals of the Rheumatic Diseases|2022|1.9k
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis
|New England Journal of Medicine|2005|1.1k